Q1 FY27 results analysis · August 03, 2026

Blue Jet Healthcare Q1 FY27 Results Analysis: Revenue Slips 17%, Gross Margin Improves 478 bps (BLUEJET)

−14.2%PAT year on year, Rs. 78.26 Cr
Cofacto ResearchPublished August 03, 20262 min readNeutral read
Quick summary

Blue Jet Healthcare Ltd's Q1 FY27 numbers came in mixed, with revenue of Rs. 293.11 Cr (-17.38% YoY) and PAT growth of -14.16% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateAugust 03, 2026
QuarterQ1 FY 2026-2027
Revenue (Q1)Rs. 293.11 Cr (-17.38% YoY)
PAT (Q1)Rs. 78.26 Cr (-14.16% YoY)
EBITDA margin33.46% (-64 bps YoY)
EPS (Q1)Rs. 4.51 (-14.26% YoY)
Market capRs. 12,147.64 Cr
CMPRs. 641.80

Quarter Snapshot

Blue Jet Healthcare reported Q1 revenue decline of 17.38% YoY due to a high base, but sequential recovery of 24.91% QoQ signals PI/API destocking reversal. Gross margin improved 478 bps YoY, and the company raised Rs.800 Cr via QIP post-quarter. However, FY27 double-digit growth guidance faces a challenging start, and freight cost inflation is pressuring other expenses.

Key Investment Insights

Key Positives

  • Revenue recovered 24.91% sequentially from Q4FY26 trough, indicating PI/API destocking reversal
  • Gross margin expanded 478 bps YoY to 53.22% from 48.44%, driven by favorable product mix
  • EBITDA margin improved 309 bps sequentially to 33.46% from 30.37% in Q4FY26
  • Company raised Rs.800 Cr via QIP post-quarter, strengthening balance sheet for capex and growth

Risk Factors

  • Revenue declined 17.38% YoY, putting FY27 double-digit growth guidance at risk
  • Other expenses rose to 12.90% of revenue from 9.43% YoY due to freight cost inflation
  • Employee costs increased 15.43% YoY, reflecting headcount additions for new projects
  • Contingent tax liability of Rs.193.39 Cr remains unresolved, with only Rs.16.5 Cr deposited under protest

Ask about this

Ask Cofacto a question about this result. Answers cite filings and company data.

Companies on this page

Related

Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.